Published in Mol Immunol on January 16, 2013
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
Natural killer cells modulation in hematological malignancies. Front Immunol (2013) 0.88
Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res (2016) 0.88
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J Immunol Res (2014) 0.82
Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. J Leukoc Biol (2016) 0.77
Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia. Front Oncol (2013) 0.77
Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov (2017) 0.76
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood (2016) 0.76
STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells. Am J Transl Res (2015) 0.75
Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells. Sci Rep (2016) 0.75
Cancer treatment and the KIR-HLA system: an overview. Clin Exp Med (2017) 0.75
Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. Eur J Endocrinol (2017) 0.75
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Strain and virulence diversity in the mouse pathogen Chlamydia muridarum. Infect Immun (2009) 1.36
Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp (2011) 1.32
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther (2012) 1.29
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood (2013) 1.17
Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med (2013) 1.14
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One (2013) 1.14
Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother (2013) 1.13
Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther (2013) 1.09
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood (2012) 1.07
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep (2012) 1.07
Identification of microRNA transcriptome involved in human natural killer cell activation. Immunol Lett (2012) 1.04
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One (2013) 1.02
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res (2013) 1.00
Identification of tissue-specific genes in nasopharyngeal epithelial tissue and differentially expressed genes in nasopharyngeal carcinoma by suppression subtractive hybridization and cDNA microarray. Genes Chromosomes Cancer (2003) 0.99
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest (2016) 0.96
Cloning, expression, and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell line. J Cancer Res Clin Oncol (2003) 0.94
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer (2013) 0.90
Immunosuppression may be present within condyloma acuminata. J Am Acad Dermatol (2008) 0.90
The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res (2013) 0.89
Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother (2013) 0.86
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother (2007) 0.85
Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing gene product within or into tumors. Mol Ther (2008) 0.85
C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genet Cytogenet (2007) 0.85
Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med (2015) 0.85
MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models. Mediators Inflamm (2012) 0.84
A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices (2010) 0.83
Poly-L-lysine-modified silica nanoparticles: a potential oral gene delivery system. J Nanosci Nanotechnol (2005) 0.83
Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb) (2013) 0.82
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer (2014) 0.80
CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer (2014) 0.79
NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy (2012) 0.79
Trichosanthes kirilowii fruits inhibit non-small cell lung cancer cell growth through mitotic cell-cycle arrest. Am J Chin Med (2015) 0.78
Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol (2013) 0.78
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl) (2012) 0.77
Natural killer cells for osteosarcoma. Adv Exp Med Biol (2014) 0.77
Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother (2016) 0.76
Screening of BRD7 interacting proteins by yeast two-hybrid system. Sci China C Life Sci (2002) 0.76
Rotavirus vaccines. N Engl J Med (2006) 0.75
Cerebral infarction in the setting of moyamoya in a pediatric patient with sickle β+-thalassemia. Pediatr Hematol Oncol (2011) 0.75
Pleuropulmonary Blastoma: A Single-center Case Series of 6 Patients. J Pediatr Hematol Oncol (2017) 0.75